Obese patients with advanced cancer treated with nivolumab monotherapy face a higher risk for immune-related adverse events, suggests a new retrospective study published online on December 8 in  JAMA Oncology .

However, only obese women receiving the nivolumab monotherapy appeared to have a higher risk for grade 3 or 4 events, according...